Laboratory reagents (Норвегия - Тендер #47582832)

1. Section I
   1. Name and addresses
      SYKEHUSINNKJØP HF
      Postboks 40
      VADSØ
      9811
      Norway
      Telephone: +47 78950700
      E-mail: post@sykehusinnkjop.no
      
   2. Joint procurement
      
   3. Communication
      The procurement documents are available for unrestricted and full direct access, free of charge, at
      https://permalink.mercell.com/214858782.aspx
      Additional information can be obtained from the abovementioned addresselectronically via: https://permalink.mercell.com/214858782.aspx
      
      
   4. Type of the contracting authority:
      Body governed by public law
      
   5. Main activity:
      Health
      
2. Section II
   1. Scope of the procurement:
      1. Title:
         

         Monitoring of the drugs adalimumab, infliximab and rituximab; serum concentration and antibody tests for Bergen Hospital Trust

         Reference number: 2023/1429
         
      2. Main CPV code:
         33696500
         
      3. Type of contract:
         Supplies
         
      4. Short description:
         

         Framework agreement for the purchase of tests for measuring the concentrations of and antibodies directed against the drugs Adalimumab, Infliximab and Rituximab in human serum.

      5. Estimated total value:
         Value excluding VAT: 6 750 000.00 NOK
         
      6. Information about lots:
         This contract is divided into lots: no
   2. Description
      1. Title:
         
      2. Additional CPV code(s):
         33690000
         
      3. Place of performance:
         
      4. Description of the procurement:
         

         The purpose of the procurement is to enter into a framework agreement for the purchase of tests for measuring the concentration of and antibodies directed against the drugs Adalimumab, Infliskimab and Rituximab in human serum in patients with autoimmune inflammatory diseases (such as arthritis, Chron"s disease, ulcerative colitis, psoriasis and multiple sclerosis (MS)).

         The analyses are part of disease monitoring, where drug concentrations are monitored and the formation of unwanted antibodies (immunogenicity) is identified, which can lead to loss of effect and increase the risk of infusion reactions.

      5. Award criteria:
         Price is not the only award criterion and all criteria are stated only in the procurement documents
      6. Estimated value:
         Value excluding VAT: 6 750 000.00 NOK
         
      7. Duration of the contract, framework agreement or dynamic purchasing system:
         
         Start: 2024-01-03
         End: 2028-01-03
         This contract is subject to renewal: yes
         Description of renewals:

         Option to extend the contract for one year + one year.

      8. Information about the limits on the number of candidates to be invited:
         
      9. Information about variants:
         Variants will be accepted: no
         
      10. Information about options:
          Options: yesDescription of options:

          Tests for other biologics that can be delivered.

      11. Information about electronic catalogues:
          
          
      12. Information about European Union funds:
          The procurement is related to a project and/or programme financed by European Union funds: no
      13. Additional information:
          
3. Section III
   1. Conditions for participation:
      1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers:
         List and brief description of conditions:

         Tenderers must be registered in a company register or a trade register in the country where the tenderer is established.

         Documentation Requirement: Norwegian tenderers: Company Registration Certificate

         Foreign companies: Verification that the tenderer is registered in a professional register in the country where the tenderer is established.

      2. Economic and financial standing:
         List and brief description of selection criteria:

         Tenderers must have sufficient economic and financial capacity to fulfil the contractual obligations.

         Economic and financial capacity means that the Tenderer fulfils the following requirements:

         A credit rating of at least score A or higher, measured against the AAA Soliditet"s score or an equivalent score from another reputable credit rating agency.

         Minimum level(s) of standards possibly required:

         The contracting authority will evaluate the tenderer"s compliance with the qualification requirements in the following manner:

         Credit rating

         If a tenderer has valid reasons for not being able to provide the documentation requested by the contracting authority, the tenderer can prove his economic and financial capacity with another document, including for example a parent company guarantee, bank guarantee, etc.

         The contracting authority reserves the right to obtain a rating report from www.solidtet.no (delivered by Bisnode Credit AS/Dun & Bradstreet) to verify that a tenderer has sufficient economic and financial ability to comply with the contract obligations.

      3. Technical and professional ability:
         List and brief description of selection criteria:

         N/A

         Minimum level(s) of standards possibly required:

         N/A

      4. Information about reserved contracts:
         
   2. Conditions related to the contract:
      1. Information about a particular profession:
         
      2. Information about staff responsible for the performance of the contract:
         
4. Section IV
5. Description:
   1. Type of procedure:
      Open procedure
   2. Information about a framework agreement or a dynamic purchasing system:
      Framework agreement with a single operatorIn the case of framework agreements, provide justification for any duration exceeding 4 years:

      Changing the method involves major reorganisations in the routine operations of the laboratory. Verification of a new method is extensive and resource-intensive, both in terms of time and personnel. Changing the method would also entail reduced patient safety due to increased response time during the transition as well as an increased risk of incorrect responses during the transition between the old and new method. See the complete justification in the Contest Provisions.

   3. Information about reduction of the number of solutions or tenders during negotiation or dialogue:
      
   4. Information about negotiation:
      
   5. Information about electronic auction:
      
   6. Information about the Government Procurement Agreement (GPA):
      The procurement is covered by the Government Procurement Agreement: yes
6. Administrative information:
   1. Previous publication concerning this procedure:
      
   2. Time limit for receipt of tenders or requests to participate:
      Date: 2023-11-24
      Local time: 12:00
      
   3. Estimated date of dispatch of invitations to tender or to participate to selected candidates:
      
   4. Languages in which tenders or requests to participate may be submitted:
      NO
   5. Minimum time frame during which the tenderer must maintain the tender:
      (from the date stated for receipt of tender)
      
   6. Conditions for opening of tenders:
      Date: 2023-11-24
      Local time: 12:00
      

Источник закупки

Импорт - Экспорт по стране Норвегия